Please login to the form below

Not currently logged in
Email:
Password:

Clovis Oncology

This page shows the latest Clovis Oncology news and features for those working in and with pharma, biotech and healthcare.

Analysts lukewarm on GSK’s new cancer acquisition

Analysts lukewarm on GSK’s new cancer acquisition

There are plenty of industry observers suggesting GSK is paying too much for Tesaro as it tries to rebuild its oncology pipeline pretty much from scratch, particularly as it spent $13bn ... leading rival Lynparza (olaparib) and two further entrants –

Latest news

  • GSK buys cancer firm Tesaro for $5.1bn GSK buys cancer firm Tesaro for $5.1bn

    of the year – gives GSK rights to approved PARP inhibitor Zejula (niraparib), which is jostling for market share with AstraZeneca's Lynparza (olaparib) and Clovis Oncology's Rubraca (rucaparib). ... Following behind are two other immuno-oncology

  • AZ and Clovis PARP inhibitors show their mettle at ESMO AZ and Clovis PARP inhibitors show their mettle at ESMO

    There was good news at the ESMO conference for both AstraZeneca and Clovis Oncology as they push to extend the use of their PARP inhibitors into new cancer patient groups. ... extend its lead over its PARP inhibitor rivals, Tesaro's Zejula (niraparib)

  • A look ahead to key trial readouts at ESMO A look ahead to key trial readouts at ESMO

    New combinations and novel mechanisms on show. The countdown to Europe’s premier oncology conference ESMO has begun, and once again it promises to deliver an astonishing array of new studies ... In breast cancer, Novartis will be presenting its SOLAR-1

  • China’s BeiGene raises $903m from Hong Kong IPO China’s BeiGene raises $903m from Hong Kong IPO

    It’s also in earlier-stage trials for other solid tumours, including glioblastoma.  It’s a potential rival to marketed PARP inhibitors from AstraZeneca (Lynparza), Clovis Oncology (Rubraca) and Tesaro (Zejula).

  • Maintenance OK boosts AstraZeneca’s Lynparza in Europe Maintenance OK boosts AstraZeneca’s Lynparza in Europe

    The drug is the second to be approved for use in this setting after Tesaro’s PARP drug Zejula (niraparib), and ahead of another rival – Clovis Oncology’s Rubraca (rucaparib) – for ... That is another key element in its defence of the brand, as is

More from news
Approximately 5 fully matching, plus 22 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Roche's Julie Warner joins Boyds Roche's Julie Warner joins Boyds

    She has previously held positions at Clovis Oncology UK, Genzyme and Gregory Fryer Associate, and was most recently senior regulatory programme manager at Roche.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Grace Communications

Grace Communications is an award winning, independent, full service, creative communications agency specialising in solving problems for healthcare brands....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics